Implications of Heterotypic Cell Fusion in Cancer.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanistic concepts and biomarker applications
PubMed 42168749 · doi:10.1007/978-3-032-22637-2_14
What was done
This narrative review synthesizes evidence on the generation, biological characteristics, and clinical relevance of hybrid cells produced via heterotypic cell fusion between neoplastic cells and tumor microenvironment cells (predominantly macrophages). It specifically examines their involvement across the metastatic cascade and the potential utility of circulating hybrid cells as peripheral blood biomarkers.
What was found
The abstract provides a conceptual overview without numerical data or quantitative metrics. It reports that tumor-immune fusion progeny co-express parental features (epithelial and immune markers), undergo functional reprogramming, and promote tumorigenesis, metastatic spread, and treatment resistance. It also notes that circulating hybrid cells have demonstrated utility for early cancer detection, risk stratification, and tracking disease progression.
Why it matters
The review highlights tumor-immune cell fusion as an important contributor to metastatic dissemination and treatment failure, underscoring circulating hybrid cells as candidates for liquid biopsy and clinical disease monitoring.
Limits
This publication is a narrative review that reports no primary clinical or experimental data, sample sizes, effect estimates, or systematic review methodology. Specific diagnostic accuracy metrics and therapeutic targets for circulating hybrid cells are not detailed in the abstract.